Skip to main content
Premium Trial:

Request an Annual Quote

Nitto Denko Advances RNAi Fibrosis Drug into Phase Ib

Premium

NEW YORK (GenomeWeb) – Japan's Nitto Denko announced this month that it has initiated a Phase Ib study of its siRNA-based fibrosis treatment ND-L02-s0201, just months after the drug successfully completed a Phase Ia safety study in healthy volunteers.

ND-L02-s0201 comprises siRNAs targeting heat shock protein 47, a collagen-specific chaperone required for the biosynthesis and secretion of collagen, and is delivered using vitamin A-coupled lipid nanoparticles. The drug's payload is based on siRNA technology Nitto Denko licensed from Quark Pharmaceuticals in 2010.

The open-label Phase Ib trial, which is being run in the US in collaboration with contract research firm RRD International, is set to enroll up to 24 patients with moderate to extensive hepatic fibrosis. Participants will receive doses of ND-L02-s0201 either once a week or twice a week for five consecutive weeks, and then be observed through week 24.

The study is designed to evaluate the safety and efficacy of the therapy.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.